ReviewFrontiers in immunology2025
The role of chemerin, elafin, and visfatin in the pathogenesis of atopic dermatitis.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic Dermatitis is a chronic skin condition characterized by inflammation and itching. It has a genetic component, but environmental factors also play a significant role. The immune system is overactive, leading to an abnormal inflammatory response. Literature data indicate that numerous proteins contribute to the development and progression of atopic dermatitis, like antimicrobial peptides, alarmins, autoantigens, cytokines, growth factors, and proteases. To synthesize current knowledge and identify the most promising contributors of AD pathogenesis a literature search was conducted using PubMed (1990-present), Google Scholar, and Embase, has been performed appropriate search terms. This narrative review summarizes the current knowledge on how elafin, chemerin, and nicotinamide phosphoribosyltransferase (visfatin/NAMPT) contribute to the pathophysiology of skin inflammation in atopic dermatitis. Recent discoveries have highlighted the importance of these proteins as important players in the functioning of the epidermal barrier. Importantly, some proteins exert anti-inflammatory effects (e.g., elafin), some pro-inflammatory effects, such as visfatin/NAMPT or chemerin, which exhibits both pro- and anti-inflammatory properties. This makes them intriguing candidates for modulating the complex inflammatory processes associated with atopic dermatitis. A deeper understanding of the role of these proteins may provide a basis for the development of appropriate treatments for atopic dermatitis. However, knowledge about the importance of these proteins in the pathological mechanisms of atopic dermatitis is still limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.